【摘要】 目的:探索出一种不中断母乳喂养、不需住院、简便有效的治疗母乳性黄疸的方法。方法:将84例足月正常体重、中度母乳性黄疸的患儿随机分成3个治疗亚组,思密达组、光疗组、鲁米那一可拉明组对照比较其疗效和对母乳喂养的影响,并检测母乳和新生儿粪便中β-葡萄糖醛酸苷酶(β-GD)的活性浓度,探讨思密达治疗母乳性黄疸的机理。结果:思密达治疗母乳性黄疸的疗效介于光疗与鲁米那一可拉明之间。每日平均胆红素下降的幅度36.36±10.12μmol／L,平均疗程为4.82±1.10 d,7 d治愈率为100％。结论:思密达治疗母乳性黄疸,安全有效,不需中断母乳喂养,有利于巩固爱婴医院成果。β-GD不是母乳性黄疸发病的主要机制,也不是通过影响β-GD而起作用。更多还原

【Abstract】 Objective: To explore a simple and effective treatment methods of breast-milk jaundice without discontinuation of breast-feeding and hospitalization by studying the efficacy of Smecta. Methods: 84 AGA infants with breast-milk jaundice were randomly grouped into three treatment sub-groups, i. e. Smecta group, photo-therapy group, luminal-coramine group, for comparison of treatment efficacies of such methods and their effect on breast-feeding. The activity condensations of β-GD in breast milk and newborns’ egesta were tested to explore the mechanism of treatment of breast-milk jaundice by Smecta. Results: The therapeutic efficacy of Smecta is intervenient between photo-therapy and luminal-coramine, with daily average cholerythrin decrease up to 36. 36±10.12 μmol/L, average treatment period 4. 82±1.10 days, 100% recovery within 7 days, without hospitalization and discontinuation of breast-feeding. Conclusion: Smecta is safe and effective in treating breast-milk jaundice without discontinuation of breast-feeding, favorable for reinforcing the results of baby-friendly hospitals. β-GD is not the main mechanism of morbidity of breast-milk jaundice and Smecta doesn’t function through influencingβ-GD.更多还原